Irsogladine maleate ameliorates inflammation and fibrosis in mice with chronic colitis induced by dextran sulfate sodium
- 591 Downloads
Intestinal fibrosis is a common and severe complication of inflammatory bowel disease (IBD), especially Crohn’s disease (CD). To investigate the therapeutic approach to intestinal fibrosis, we have developed a mouse model of intestinal fibrosis by administering dextran sulfate sodium (DSS) and examining the effects of irsogladine maleate (IM) [2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate], which has been widely used as an antiulcer drug for gastric mucosa in Japan, on DDS-induced chronic colitis. In this experimental colitis lesion, several pathognomonic changes were found: increased deposition of collagen, increased number of profibrogenic mesenchymal cells such as fibroblasts (vimentin+, α-SMA−) and myofibroblasts (vimentin+, α-SMA+) in both mucosa and submucosa of the colon with infiltrating inflammatory cells, and increased mRNA expressions of collagen type I, transforming growth factor (TGF)-β, matrix metalloproteinase (MMP)-2, and tissue inhibitor of matrix metalloproteinase (TIMP)-1. When IM was administered intrarectally to this colitis, all these pathological changes were significantly decreased or suppressed, suggesting a potential adjunctive therapy for intestinal fibrosis. IM could consequently reduce fibrosis in DSS colitis by direct or indirect effect on profibrogenic factors or fibroblasts. Therefore, the precise effect of IM on intestinal fibrosis should be investigated further.
Key wordsIrsogladine maleate Inflammatory bowel disease Crohn’s disease Fibrosis Mesenchymal cells TGF-β
Unable to display preview. Download preview PDF.
- 7.Hiraishi H, Haruma K, Miwa H, Goto H (2010) Clinical trial: irsogladine maleate, a mucosal protective drug, accelerates gastric ulcer healing after treatment for eradication of Helicobacter pylori infection: the results of a multicentre, double-blind, randomized clinical trial (IMPACT study). Aliment Pharmacol Ther 31(8): 824–833PubMedGoogle Scholar
- 8.Murakami K, Okimoto T, Kodama M, Tanahashi J, Mizukami K, Shuto M, Abe H, Arita T, Fujioka T (2011) Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study. Scand J Gastroenterol 46(3):287–292PubMedCrossRefGoogle Scholar
- 18.Fujita T, Kishimoto A, Shiba H, Hayashida K, Kajiya M, Uchida Y, Matsuda S, Takeda K, Ouhara K, Kawaguchi H, Abiko Y, Kurihara H (2010) Irsogladine maleate regulates neutrophil migration and E-cadherin expression in gingival epithelium stimulated by Aggregatibacter actinomycetemcomitans. Biochem Pharmacol 79(10):1496–1505PubMedCrossRefGoogle Scholar
- 25.Dielman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO (1994) Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107:1643–1652Google Scholar
- 32.Ueda F, Aratani S, Mimura K, Kimura K, Nomura A, Enomoto H (1984) Effect of 2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate (MN-1695) on gastric mucosal damage induced by various necrotizing agents in rats. Arzneim-Forsch 34:478–484Google Scholar
- 34.Hara K, Ueda F (1996) Effect of irsogladine maleate on indomethacin-induced intestinal ulcers and trinitrobenzene sulfonic acidinduced colonic ulcers in rats. Jpn Pharmacol Ther 24:2143–2149Google Scholar
- 39.Pucilowska JB, Williams KL, Lund PK (2000) Fibrogenesis IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol Gastrointest Liver Physiol 279:G653–G659Google Scholar